Glen Harbor Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Glen Harbor Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-19,908	Closed	-$125K	–	1358
2018 Q3	$125K	Buy	19,908 +1,428	+8%	+$11K	﹤0.01%	1163
2018 Q2	$148K	Hold	18,480	–	–	﹤0.01%	1065
2018 Q1	$138K	Buy	18,480 +4,340	+31%	+$28.9K	﹤0.01%	1085
2017 Q4	$84K	Buy	14,140 +3,584	+34%	+$21.8K	﹤0.01%	1176
2017 Q3	$78K	Buy	10,556 +2,548	+32%	+$16.2K	﹤0.01%	1160
2017 Q2	$54K	Buy	8,008 +4,284	+115%	+$31.6K	﹤0.01%	1188
2017 Q1	$35K	Buy	+3,724	New	+$37.2K	﹤0.01%	1184

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Glen Harbor Capital Management's PGNX Position: Q4 2018 in Review

Glen Harbor Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2018, closing a stake of 19,908 shares — an estimated $125K sold.

Glen Harbor Capital Management first reported a position in PGNX in Q1 2017 and held it in 7 quarters. The position peaked at $148K in Q2 2018. 150 funds tracked by Wall St. Rank hold PGNX as of Q4 2018.

Glen Harbor Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
Glen Harbor Capital Management sold 19,908 Progenics Pharmaceuticals Inc shares in Q4 2018, an estimated $125K.
Glen Harbor Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 7 quarters.
Glen Harbor Capital Management's Progenics Pharmaceuticals Inc position peaked at $148K in Q2 2018.
150 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2018.

Based on Glen Harbor Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.